TRHC - Tabula Rasa Healthcare, Inc

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by T0rm3nted, Oct 25, 2016.

  1. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,460
    Likes Received:
    3,279
    Will add chart when Finviz adds TRHC
    Tabula Rasa HealthCare, Inc. (TRHC), formerly CareKinesis, Inc., is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It also provides risk adjustment services, which help its clients to properly characterize a patient's acuity, or severity of health condition, and optimize the associated payments for care. The Company serves approximately 100 healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. Its products and services are built around the Medication Risk Mitigation Matrix, or MRM Matrix.
     
  2. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,460
    Likes Received:
    3,279
    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    UBS
    Change: Coverage Initiated
    Previous Rating: N/A
    Current Rating: Buy
    Previous Price Target: N/A
    Current Price Target: $18

    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Wells Fargo
    Change: Coverage Initiated
    Previous Rating: N/A
    Current Rating: Outperform
    Previous Price Target: N/A
    Current Price Target: N/A

    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Stifel
    Change: Coverage Initiated
    Previous Rating: N/A
    Current Rating: Buy
    Previous Price Target: N/A
    Current Price Target: $17

    Analyst Upgrade/Downgrade Update

    Brokerage firm: Robert W. Baird
    Change: Coverage Initiated
    Previous Rating: N/A
    Current Rating: Outperform

    Previous Price Target: N/A
    Current Price Target: $17


    Analyst Upgrade/Downgrade Update

    Brokerage firm: Piper Jaffray
    Change: Coverage Initiated
    Previous Rating: N/A

    Current Rating: Overweight
    Previous Price Target: N/A
    Current Price Target: N/A
     
  3. anotherdevilsadvocate

    anotherdevilsadvocate Well-Known Member

    Joined:
    Apr 3, 2016
    Messages:
    4,333
    Likes Received:
    3,380
    Trading near the lows for the year, and reporting in a week (Nov 3).
    Possible short squeeze with ~30% of the float short. Or the shorts are right and this trades lower :cool:
    [​IMG]
     

Share This Page